Pharmaceutical Drying Equipment Market Size & Forecast 2035
The global pharmaceutical drying equipment market size was valued at US$6.17 billion in 2025 and is projected to reach US$11.80 billion by 2035, growing at a CAGR of 6.7% during 2026–2035.
Pharmaceutical drying equipment comprises GMP-compatible systems used to remove water or organic solvents from active pharmaceutical ingredients, intermediates, excipients, biologics and finished drug products. Drying directly influences residual moisture, particle characteristics, product stability, sterility, potency, dissolution and shelf life.
Demand is being supported by rising biologics and sterile-drug production, investment in pharmaceutical manufacturing capacity, growth of contract development and manufacturing organizations, and the need to replace labor-intensive equipment with automated and validated systems.
Equipment selection is becoming more application-specific. Freeze dryers are widely used for temperature-sensitive biologics, vaccines, and sterile injectables, while spray dryers support particle engineering and amorphous solid dispersions. Fluid-bed systems are important in oral solid-dose manufacturing, and vacuum or filter dryers are commonly selected for active pharmaceutical ingredients and contained processing.
Pharmaceutical Drying Equipment Market Scope
| Metrics | Details |
| Market Size in 2025 | US$6.17 Billion |
| Forecast Value in 2035 | US$11.80 Billion |
| CAGR | 6.70% |
| By Equipment Type | Freeze Dryers, Spray Dryers, Fluid-Bed Dryers, Vacuum Dryers, Filter Dryers, Tray and Oven Systems, Other Emerging Systems |
| By Mode of Operation | Batch, Semi-Continuous and Continuous |
| By Scale | Laboratory and Development, Pilot and Clinical Manufacturing, Commercial GMP Production |
| By Application | APIs, Intermediates, Oral Solid-Dose Granules, Biologics, Vaccines, Sterile Injectables, Peptides and Proteins, Amorphous Solid Dispersions, Inhalation Products, Diagnostic Materials |
| By End User | Pharmaceutical Companies, Biotechnology Companies, API Manufacturers, Vaccine Manufacturers, CDMOs, CROs, Diagnostic Companies, Research Institutions |
| By Region | North America, South America, Europe, Asia-Pacific, Middle East and Africa |
| Largest Market | North America |
| Fastest-Growing Region | Asia-Pacific |
| Revenue Coverage | New Equipment, Integrated Drying Lines, Controls, Loading Systems, Installation, Commissioning and Defined Aftermarket Services |
The market excludes general industrial dryers, food-processing equipment, pharmaceutical products manufactured using drying systems, and contract drying revenue unless separately identified.
Pharmaceutical Drying Equipment Market Key Takeaways
- The market is expected to create approximately US$5.63 billion in additional revenue opportunities between 2025 and 2035.
- North America remains the largest market, supported by advanced pharmaceutical manufacturing, biologics production, regulatory compliance requirements and early adoption of automated systems.
- Asia-Pacific is expected to record the fastest growth as China, India, Japan, South Korea and Singapore expand pharmaceutical, biotechnology and contract-manufacturing capacity.
- Spray dryers remain an important commercial segment because they support rapid drying, particle engineering and continuous production across several pharmaceutical applications.
- Freeze dryers are expected to gain importance as manufacturers expand production of biologics, vaccines, peptides and sterile products that are unstable in liquid form.
- CDMOs represent an attractive customer group because they require flexible, multiproduct equipment that can support different formulations, batch sizes and containment requirements.
- Automated loading, recipe management, endpoint monitoring, data integrity and integration with process analytical technology are becoming important purchasing criteria.
- Equipment pricing alone does not determine procurement value. Validation cost, utility demand, maintenance, cycle time, yield and downtime can materially affect total ownership cost.
Pharmaceutical Drying Equipment Market Trends
Freeze-Drying Capacity Expands with Biologics Production
Freeze drying, or lyophilization, removes water after the product is frozen and placed under vacuum. The process involves freezing, primary drying through sublimation and secondary drying through desorption.
It is widely used for products that cannot maintain adequate stability in liquid form, including biologics, vaccines, proteins, peptides and sterile injectable formulations. GEA describes pharmaceutical freeze drying as particularly suited to sensitive, mainly biological products that require longer storage and later reconstitution.
Purchasing decisions increasingly focus on shelf area, condenser capacity, chamber uniformity, loading automation, clean-in-place capability, sterilize-in-place capability and integration with aseptic filling lines.
Conventional industrial lyophilization remains largely batch based. Continuous and microwave-assisted approaches are being developed to reduce cycle time, energy demand and process bottlenecks, but adoption remains dependent on scale-up evidence and regulatory acceptance.
Spray Drying Supports Particle Engineering
Spray drying converts a liquid feed into a dry powder through atomization and rapid contact with a heated drying gas. The short residence time can support heat-sensitive products when the process is correctly designed.
The technology is used for amorphous solid dispersions, inhalation powders, antibiotics, enzymes, formulation intermediates and selected biologic products. It allows manufacturers to influence particle size, density, morphology, flow and dissolution characteristics. GEA identifies pharmaceutical spray drying as a flexible method for designing powder properties and producing improved drug formulations.
Demand is increasing for closed-loop, high-containment and aseptic spray-drying systems. These configurations require higher investment but can support potent compounds, organic solvents and sterile applications.
Automation Strengthens Process Control
Modern drying systems increasingly include automated recipe management, electronic batch records, audit trails, endpoint detection and remote service capabilities.
Automation reduces dependence on manual adjustments and supports consistent operation across batches. It also improves traceability during qualification, technology transfer and regulatory review.
In freeze drying, important parameters include shelf temperature, chamber pressure, product temperature and primary-drying endpoint. Spray-drying systems require control of inlet temperature, outlet temperature, atomization pressure, feed rate and gas flow. Fluid-bed processes depend on airflow, inlet temperature, product temperature and moisture endpoint.
Energy Efficiency Becomes a Procurement Criterion
Drying can be one of the most energy-intensive stages in pharmaceutical production. Freeze dryers require refrigeration and vacuum generation, while spray dryers consume energy to heat and circulate process gas.
Vendors are introducing low-global-warming-potential refrigerants, heat-recovery systems, improved vacuum controls and cycle-optimization tools. The EU’s updated fluorinated greenhouse-gas regulation is also influencing refrigeration choices in freeze-drying equipment.
Energy efficiency is increasingly evaluated alongside process performance because it affects operating expenditure, sustainability targets and long-term equipment compliance.
Pharmaceutical Drying Equipment Market Dynamics
Pharmaceutical Production Expansion Drives Equipment Demand
Growth in pharmaceutical manufacturing is increasing the number of facilities requiring validated drying capacity. Demand is particularly strong in biologics, vaccines, sterile injectables, high-potency APIs, oral solid doses and advanced formulations.
Drying systems influence whether a product achieves its intended stability and quality profile. Manufacturers therefore evaluate equipment as part of the product-control strategy rather than as an isolated utility.
The expansion of CDMOs further supports demand for scalable and flexible systems. Contract manufacturers may need laboratory, pilot and commercial equipment that can support multiple customers without excessive cleaning or changeover time.
Regulatory Expectations Encourage Validated Systems
Pharmaceutical manufacturers must demonstrate that processes consistently produce products with the required identity, strength, quality and purity. FDA process-validation guidance emphasizes lifecycle-based understanding and control of pharmaceutical manufacturing processes.
For drying equipment, this creates requirements around:
- Installation qualification
- Operational qualification
- Performance qualification
- Cleaning validation
- Sterilization validation
- Calibration
- Electronic records
- Data integrity
- Alarm management
- Change control
- Preventive maintenance
Quality-by-design principles also encourage manufacturers to understand the relationship between process parameters, equipment performance and critical product attributes.
High Capital and Validation Costs Restrict Adoption
Advanced freeze dryers, aseptic spray dryers and contained filter dryers require substantial capital investment. Buyers may also need facility changes, utilities, cleanrooms, isolators and specialized automation.
Qualification and validation can extend the time between equipment purchase and commercial operation. Delays may become particularly expensive when the system is linked to a new drug launch or capacity-expansion program.
Smaller manufacturers may continue using tray dryers, conventional ovens or refurbished systems where process requirements permit. Refurbished equipment can lower acquisition cost but may create risks related to documentation, spare parts, control-system obsolescence and regulatory suitability.
Skilled Workforce Shortages Increase Implementation Risk
Drying-process development requires expertise in formulation science, heat and mass transfer, automation, sterile processing and scale-up.
A system that performs adequately at laboratory scale may require substantial modification at commercial scale. Incorrect assumptions about heat transfer, atomization or product loading can affect yield, moisture uniformity and cycle duration.
Equipment vendors offering process-development support, pilot testing and scale-up services may therefore hold an advantage over suppliers competing primarily on equipment price.
Pharmaceutical Drying Equipment Segment Analysis
Spray Dryers Hold a Significant Market Position
Spray dryers account for a substantial share of the market because they offer rapid processing, scalable production and control over powder characteristics.
They are particularly valuable for amorphous solid dispersions intended to improve the bioavailability of poorly soluble drugs. Spray drying can also support dry-powder inhalation products and formulation intermediates.
The segment includes open-cycle, closed-loop, aseptic and high-containment systems. Selection depends on solvent use, explosion risk, potency, sterility and target powder properties.
Freeze Dryers Record Strong Growth
Freeze dryers are expected to expand as the pharmaceutical pipeline shifts toward biologics and other temperature-sensitive molecules.
FDA guidance notes that lyophilized products require close attention to potency, sterility and manufacturing control. Equipment uniformity is important because different vial positions can experience different heat-transfer conditions during the drying cycle.
Production systems may include automatic loading and unloading, vial-handling systems, stoppering capability, isolators and integrated control platforms. These features support aseptic processing but increase capital cost and validation complexity.
Fluid-Bed Dryers Support Oral Solid-Dose Manufacturing
Fluid-bed dryers are commonly used to dry wet granules in tablet and capsule production. Integrated fluid-bed granulation and drying can reduce material transfers and shorten processing time.
The equipment offers relatively efficient heat and mass transfer, but process control is necessary to avoid uneven moisture, excessive granule attrition or changes in particle characteristics.
Continuous fluid-bed systems are attracting interest from manufacturers seeking more consistent throughput and lower work-in-process inventory.
Vacuum and Filter Dryers Support API Processing
Vacuum dryers operate at reduced pressure, allowing solvents or moisture to be removed at lower temperatures. They are suitable for heat-sensitive APIs and intermediates.
Agitated Nutsche filter dryers combine filtration, washing and drying in an enclosed system. They can reduce product handling and support containment for potent or hazardous compounds.
Important selection criteria include agitation design, filter area, vacuum performance, cleaning capability, material compatibility and containment level.
Pharmaceutical Dryer Selection Framework
| Selection Factor | Freeze Drying | Spray Drying | Fluid-Bed Drying | Vacuum or Filter Drying |
| Typical Application | Biologics and Sterile Products | Engineered Powders and ASDs | Oral Solid-Dose Granules | APIs and Intermediates |
Heat-Sensitive Products | Excellent | Application Dependent | Moderate | Strong |
| Sterile Capability | Strong | Available in Specialized Systems | Limited by Configuration | Available |
| Particle Engineering | Limited | Excellent | Moderate | Limited |
| Continuous Operation | Emerging | Established | Available | Configuration Dependent |
| Capital Intensity | Very High | High | Moderate | Moderate to High |
| Containment Capability | Strong | Strong in Specialized Systems | Available | Strong |
| Main Scale-Up Risk | Heat and Mass Transfer | Atomization and Solvent Removal | Fluidization Uniformity | Mixing and Drying Uniformity |
The final selection should also consider batch size, target residual moisture, solvent system, product potency, sterility, final dosage form, available utilities and cleaning strategy.
Total Cost of Ownership
The true equipment cost extends beyond the purchase price.
A total-cost assessment should include:
- Equipment acquisition
- Facility preparation
- Utilities and cleanroom modifications
- Installation and commissioning
- Qualification and validation
- Energy and processing gas
- Vacuum and refrigeration maintenance
- Filters and consumables
- Cleaning and sterilization
- Software support
- Spare parts
- Training
- Product loss
- Downtime
- Decommissioning
A higher-priced system may provide better lifetime economics if it reduces drying time, improves yield, lowers changeover time or avoids production failures.
Regional Analysis
North America
North America held the largest share of the pharmaceutical drying equipment market in 2025.
The United States leads regional demand because of its large pharmaceutical and biotechnology industry, advanced sterile manufacturing, strong CDMO presence and early adoption of automated production technologies.
The market offers significant opportunities in biologics lyophilization, aseptic spray drying, high-potency containment and replacement of aging manufacturing systems.
Europe
Europe remains an important pharmaceutical manufacturing and engineering market. Germany, Italy, Switzerland, Ireland, France and the United Kingdom support demand through API production, sterile-drug manufacturing, biologics and equipment exports.
European buyers increasingly assess refrigerants, energy use, solvent recovery and lifecycle emissions alongside product quality and compliance.
The region also benefits from established manufacturers of freeze dryers, spray dryers, fluid-bed systems and contained API-processing equipment.
Asia-Pacific
Asia-Pacific is expected to grow fastest during 2026–2035.
China and India are expanding pharmaceutical, generic-drug, API and CDMO capacity. Japan and South Korea support demand through biologics, vaccines and advanced therapeutic manufacturing, while Singapore remains an important location for international pharmaceutical investment.
The region offers high-volume opportunities but remains sensitive to equipment pricing, local service availability and qualification support.
Competitive Landscape
The market includes integrated pharmaceutical-equipment companies and specialized suppliers focused on individual drying technologies.
Major companies include:
- GEA Group
- Syntegon Telstar
- IMA Group
- OPTIMA Packaging Group
- Hosokawa Micron
- FREUND Corporation
- Büchi Labortechnik
- Glatt Group
- ATS Corporation and SP Industries
- Martin Christ
- Millrock Technology
- Labconco
- De Dietrich Process Systems
- GMM Pfaudler
- HEINKEL Drying and Separation Group
- L.B. Bohle
- Romaco Group
- European SprayDry Technologies
Vendors compete through equipment range, process-development capability, sterile design, containment, automation, loading systems, validation support, service coverage and delivery time.
In February 2026, GEA published updated technical guidance on pharmaceutical freeze drying, emphasizing the role of lyophilization in stabilizing sensitive biological products. The company is also developing microwave-assisted freeze-drying concepts intended to shorten cycles and reduce energy use.
How This Report Supports Commercial Decisions
The report helps pharmaceutical manufacturers, CDMOs, investors and equipment suppliers evaluate:
- Which drying technology best fits a product pipeline
- Whether drying capacity should be installed internally or outsourced
- Required laboratory, pilot and commercial capacity
- Equipment demand by molecule and dosage form
- Validation and facility requirements
- Batch versus continuous production
- Total ownership cost
- Energy and sustainability performance
- Vendor capabilities and service networks
- Regional pharmaceutical-capacity expansion
- Partnership, distribution and acquisition opportunities
- Replacement and aftermarket revenue potential
Suggestions for Related Report
For more pharmaceutical-related reports, please click here
